Based on current RS Ratings, the strongest Pharmaceuticals & Biotechnology stocks in India are Transchem Ltd. (RS 99), Bafna Pharmaceuticals Ltd. (RS 99), Morepen Laboratories Ltd. (RS 99). These stocks have the highest relative strength compared to all other stocks in the market. RS Rating is updated daily on sharpely. Currently, 58 of 243 stocks (24%) in this group have an RS Rating above 80, placing them in the market's strongest 20%.
Pharmaceuticals & Biotechnology Stocks in India
243 stocks · 2 industriesNSE Industry GroupPart of Healthcare sectorUpdated 13 Oct 2026
Market Statistics
Breadth — stocks above 200 EMA
57%
Moderate — 57% above 200 EMA
RS Rating — in market's strongest 20%
58 of 243
24% of stocks are top performers
Average P/E
35.0x
Industry group average
Stocks outperforming Nifty 50 (1Y)
58.6%
Moderate — 58.6% beat Nifty
Current outlook
Auto‑updated dailyThe Pharmaceuticals & Biotechnology industry group shows moderate breadth - 57% of 243 stocks above 200 EMA. On the relative strength front, 58 of 243 stocks (24%) carry an RS Rating in the market's strongest 20%, indicating strong relative performance and quality.
From a valuation perspective, fair valuation - the group trades at a average P/E of 35.0x, in line with the sector average of 35.2x. Meanwhile, moderate relative performance — 58.6% of stocks beat Nifty 50 in the last year.
Within the group, Pharmaceuticals shows the strongest breadth at 57% above 200 EMA, while Biotechnology is lagging at 33%. The difference suggests more uniform participation across sub‑industries.
Last updated: 13 Oct 2026 · Based on end‑of‑day data
Top stocks by RS Rating
58 of 243 stocks (24%) are in the market's strongest 20% — showing top 4 stocks by RS Rating
All stocks in Pharmaceuticals & Biotechnology
243 stocks across 2 industries
Stocks
237
P/E
34.7x
ROCE
14.3%
Above 200 EMA
57%
RS Stars
58 of 237
| Company | RS Rating | Market Cap (Cr) | P/E | ROCE % | PAT Margin % | 1Y Return | 200 EMA |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd. | 59 | 4,22,283 | 34.9 | 16.6 | 20.2 | +7.8% | ↓ No |
Divis Laboratories Ltd. | 90 | 2,50,231 | 85.5 | 18.8 | 26.0 | +60.7% | ↑ Yes |
Torrent Pharmaceuticals Ltd. | 72 | 1,78,088 | 81.6 | 15.8 | 13.9 | +33.2% | ↑ Yes |
Zydus Lifesciences Ltd. | 75 | 1,13,157 | 25.1 | 16.2 | 15.8 | +14.8% | ↑ Yes |
Laurus Labs Ltd. | 96 | 1,11,801 | 102.3 | 17.0 | 15.0 | +139.1% | ↑ Yes |
Cipla Ltd. | 52 | 1,05,936 | 31.4 | 14.5 | 11.9 | -13.5% | ↓ No |
Dr. Reddys Laboratories Ltd. | 60 | 1,02,408 | 31.8 | 11.2 | 9.7 | -1.5% | ↓ No |
Mankind Pharma Ltd. | 66 | 99,130.797 | 48.5 | 11.9 | 13.9 | -2.0% | ↑ Yes |
Aurobindo Pharma Ltd. | 84 | 98,211.297 | 26.5 | 11.7 | 10.6 | +56.1% | ↑ Yes |
Lupin Ltd. | 32 | 88,485.602 | 16.6 | 27.7 | 19.1 | -1.9% | ↓ No |
Glenmark Pharmaceuticals Ltd. | 69 | 64,432 | 39.9 | 35.0 | 9.2 | +15.3% | ↑ Yes |
Alkem Laboratories Ltd. | 50 | 62,233.602 | 28.8 | 17.4 | 14.3 | -4.3% | ↓ No |
Biocon Ltd. | 47 | 56,414.398 | 113.9 | 3.5 | 2.9 | -1.7% | ↓ No |
Abbott India Ltd. | 49 | 54,822.398 | 34.0 | 39.1 | 23.1 | -13.9% | ↓ No |
Gland Pharma Ltd. | 91 | 50,797 | 45.0 | 12.0 | 16.8 | +57.7% | ↑ Yes |
Showing 15 of 237 stocksView all →
Stocks
6
P/E
59.1x
ROCE
19.3%
Above 200 EMA
33%
RS Stars
0 of 6
| Company | RS Rating | Market Cap (Cr) | P/E | ROCE % | PAT Margin % | 1Y Return | 200 EMA |
|---|---|---|---|---|---|---|---|
Anthem Biosciences Ltd. | 80 | 49,761.102 | 86.4 | 24.9 | 28.8 | +16.4% | ↑ Yes |
Advanced Enzyme Technologies Ltd. | 31 | 2,980.24 | 17.8 | 11.8 | 22.3 | -19.5% | ↓ No |
CCME Global Ltd. | — | 138.148 | — | -3.1 | — | — | ↓ No |
Vivo Bio Tech Ltd. | 2 | 32.177 | — | 7.0 | -5.2 | -61.3% | ↓ No |
Shree Ganesh Bio-Tech (India) Ltd. | 14 | 18.735 | -48.5 | -1.5 | -6.0 | -38.2% | ↓ No |
Showing 5 of 6 stocksView all →
Showing 2 of 2 industriesExplore complete stock list with fundamentals & technical data
Explore Pharmaceuticals & Biotechnology →Market breadth breakdown
Percentage of stocks in this group meeting each technical condition — updated daily
Above 200 EMA
57%
Above 200 SMA
66%
Above 50 EMA
36%
Above 50 SMA
33%
Outperf Nifty 50 (1Y)
59%
Outperf Nifty 50 (6M)
81%
Outperf Nifty 50 (3M)
61%
RSI above 70
1%
RSI below 30
9%
Near 52W High
15%